• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Fortrea Holdings Inc. filed SEC Form 8-K: Leadership Update

    7/14/26 4:05:39 PM ET
    $FTRE
    Medical Specialities
    Health Care
    Get the next $FTRE alert in real time by email
    ftre-20260708
    0001965040FALSE00019650402026-07-082026-07-080001965040us-gaap:CommonClassAMember2026-07-082026-07-08

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    July 8, 2026
    (Date of earliest event reported)

    Fortrea Holdings Inc.
    (Exact Name of Registrant as Specified in its Charter)


    Delaware
    001-41704
    92-2796441
    (State or other jurisdiction of Incorporation)
    (Commission File Number)
    (I.R.S. Employer Identification No.)

    8 Moore Drive
    Durham,
    North Carolina
    27713
    (Address of principal executive offices)
    (Zip Code)

    (Registrant’s telephone number including area code) 877-495-0816

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐
    Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Exchange Act.
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, $0.001 par valueFTREThe NASDAQ Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    Departure of Chief Accounting Officer and Appointment of Interim Principal Accounting Officer

    On July 8, 2026, Robert A. Parks informed Fortrea Holdings Inc. (the “Company”) of his intention to resign from his position as Chief Accounting Officer and principal accounting officer to pursue an opportunity outside the contract research organization industry. Mr. Parks’ resignation will be effective August 7, 2026 (the “Effective Date”). Mr. Parks’ decision to resign was not the result of any disagreement with the Company or its Board of Directors relating to the Company’s operations, policies or practices or any issues regarding its accounting policies or practices. Until the Effective Date, Mr. Parks will continue in the role of Chief Accounting Officer and principal accounting officer and assist with the transition of his responsibilities.

    On the Effective Date, Carrie Russell, the Company’s Vice President of Accounting, will be designated as and assume the responsibilities of interim principal accounting officer and interim Chief Accounting Officer in addition to her role as Vice President of Accounting, until a successor principal accounting officer and Chief Accounting Officer is appointed.

    Ms. Russell currently serves as the Company’s Vice President of Accounting, a position she has held since August 2024. As Vice President of Accounting, Ms. Russell is responsible for the Company’s accounting function, including technical accounting, accounting policy, financial close and consolidation, internal controls over financial reporting, and external financial reporting. Prior to joining the Company, Ms. Russell spent nearly 17 years with PricewaterhouseCoopers LLP (“PwC’), most recently serving as a Trust Solutions Audit Director within the Health Industries practice. Her tenure at PwC included two years in PwC's National Office SEC Services group, where she advised registrants and engagement teams on SEC reporting requirements, financial reporting matters, and the application of U.S. GAAP and SEC regulations. Ms. Russell is a Certified Public Accountant and received a Bachelor of Science in Business Administration and a Master of Accountancy from the University of North Carolina at Chapel Hill. She currently serves on the Board of Directors of the North Carolina Museum of Art Foundation.

    In connection with Ms. Russell’s appointment as interim principal accounting officer and interim Chief Accounting Officer, Ms. Russell will receive a one-time cash bonus of $20,000. In addition, during the term of her employment as interim principal accounting officer and interim Chief Accounting Officer, the Company will pay Ms. Russell an additional cash bonus of $10,000 per month, paid in accordance with the Company’s regular payroll schedule. Ms. Russell currently receives an annual base salary and is eligible to receive an annual incentive bonus and annual long-term incentive awards in the form of performance share awards and restricted stock units under the Company’s 2023 Omnibus Incentive Plan, a copy of which was filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. Ms. Russell is also eligible to participate in the Company’s other benefit plans and programs as described in the Company’s Definitive Proxy Statement for the 2026 Annual Meeting of Stockholders, filed on Schedule 14A with the Securities and Exchange Commission on April 27, 2026.

    There are no arrangements or understandings between Ms. Russell and any other person pursuant to which she was appointed as interim principal accounting officer and interim Chief Accounting Officer of the Company, and she is not a party to, nor does she have any direct or indirect material interest in, any transaction requiring disclosure under Item 404(a) of Regulation S-K. She does not have any family relations with any directors or executive officers of the Company.

    Previously Announced Departure of Chief Financial Officer

    In connection with the transition of the Chief Financial Officer position previously announced on June 26, 2026, the Company and Jill McConnell entered into an Employment Transition Agreement and General Release, dated as of July 14, 2026 (the “Transition Agreement”), whereby the Company and Ms. McConnell have mutually agreed that Ms. McConnell will continue to be employed by the Company through September 8, 2026 (the “Transition Period”) to assist in the transition. As consideration for the services provided, Ms. McConnell will remain employed by the Company at the same base pay and benefits during the Transition Period, including continued vesting under her outstanding equity awards, unless (a) Ms. McConnell earlier voluntarily resigns or (b) her employment is terminated by the Company for Cause (as defined in the Fortrea Inc. Master Senior Executive Severance Plan (the “Severance Plan”)).




    Additionally, if Ms. McConnell remains employed by the Company at the end of the Transition Period, the Company will enter into a Separation Agreement and General Release with Ms. McConnell in substantially the form attached to the Transition Agreement (the “Separation Agreement”). Pursuant to the Separation Agreement, the Company will pay Ms. McConnell severance in a total amount of $1,017,500.00, less applicable taxes and withholdings (hereafter referred to as “Severance Pay”), which equals one times Ms. McConnell’s base salary of $550,000 plus Ms. McConnell’s target annual bonus for 2026 of $467,500. The Severance Pay shall be paid in two (2) installments, with the first installment of $508,750, less taxes and withholding, made payable within thirty (30) days following the effectiveness of the Separation Agreement and the second installment of $508,750, less taxes and withholding, made payable within thirty (30) days following the one (1)-year anniversary of the effectiveness of the Separation Agreement, subject to the terms and conditions of the Severance Plan. In the event Ms. McConnell elects continuation of coverage under COBRA for herself and her dependents, the Company will pay the applicable premium for such coverage for twelve (12) months from her date of separation. The Separation Agreement contains general covenants, promises, and agreements, including Ms. McConnell’s release of claims as well as covenants not to solicit, not to compete and not to disclose confidential information.

    At the end of the Transition Period, the Company and Ms. McConnell have agreed to enter into a consulting agreement (the “Consulting Agreement”) whereby Ms. McConnell will provide additional transition services through March 8, 2027 (the “Consulting Period”). As consideration for the services provided, Ms. McConnell’s outstanding restricted stock units will continue to vest during and at the end of the Consulting Period according to their terms.

    The foregoing descriptions of the Transition Agreement (including the Separation Agreement attached thereto) and the Consulting Agreement are qualified in their entirety by the terms of the Transition Agreement (including the Separation Agreement attached thereto) and the Consulting Agreement, copies of which will be filed with the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2026.





    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


    Fortrea Holdings Inc.
    By:
    /s/ Agnieszka M. Gallagher
    Name: Agnieszka M. Gallagher
    Title: General Counsel and Secretary

    Date: July 14, 2026

    Get the next $FTRE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FTRE

    DatePrice TargetRatingAnalyst
    3/9/2026$15.00Hold → Buy
    TD Cowen
    1/8/2026$22.00Hold → Buy
    Truist
    1/6/2026$25.00In-line → Outperform
    Evercore ISI
    12/15/2025$15.00Underweight → Equal Weight
    Barclays
    12/11/2025$21.00Neutral → Buy
    Citigroup
    8/4/2025$9.00Neutral → Outperform
    Robert W. Baird
    5/2/2025$7.00Hold
    Truist
    4/10/2025$6.00Equal Weight → Underweight
    Barclays
    More analyst ratings

    $FTRE
    SEC Filings

    View All

    Fortrea Holdings Inc. filed SEC Form 8-K: Leadership Update

    8-K - Fortrea Holdings Inc. (0001965040) (Filer)

    7/14/26 4:05:39 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Holdings Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Fortrea Holdings Inc. (0001965040) (Filer)

    6/26/26 4:42:18 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Fortrea Holdings Inc. (0001965040) (Filer)

    6/12/26 4:04:27 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Knoblauch Jason Fredrick claimed ownership of 275 shares (SEC Form 3)

    3 - Fortrea Holdings Inc. (0001965040) (Issuer)

    7/15/26 5:26:41 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Director Sanders Machelle converted options into 38,817 shares, increasing direct ownership by 533% to 46,099 units (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    6/12/26 4:18:11 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Director Smith David Ross converted options into 38,817 shares and covered exercise/tax liability with 18,244 shares, increasing direct ownership by 216% to 30,117 units (SEC Form 4) (tax liability)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    6/12/26 4:17:00 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fortrea Announces Date for Second Quarter 2026 Financial Results and Conference Call

    DURHAM, N.C., July 13, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its second quarter 2026 financial results before the market opens on Wednesday, July 29, 2026. The Company will host a conference call at 8:00 a.m. ET on that day to discuss the results. To participate in the conference call, participants should pre-register via the call registration link. All registrants will receive dial-in details and a unique PIN providing access to the live call. To avoid potential delays, participants are encouraged to join at least 10 minutes prior to the start of the call. The live webca

    7/13/26 9:00:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Names Jason Knoblauch as Chief Financial Officer

    DURHAM, N.C., June 26, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that Jason Knoblauch has been appointed as chief financial officer, effective July 6, 2026. He will succeed Jill McConnell, who is stepping down after successfully helping the Company become a leading, independent global CRO, and is committed to ensuring a smooth transition. "I’m delighted to welcome Jason to the Fortrea team as we continue to make advances in our strategic journey back to growth," said Anshul Thakral, CEO of Fortrea. "At the same time, I want to recognize Jill’s contributions at Fortrea and our legacy companies. We

    6/26/26 7:00:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization ("CRO"), today announced the granting of an inducement award of restricted stock units ("RSUs") on June 10, 2026, to 10 newly hired employees. The award consisted of 240,500 RSUs that vest in three equal annual installments starting June 10, 2027, subject to the employee's continuous employment through the applicable vesting date. The RSUs are subject to the terms and conditions of the Company's Amended and Restated 2025 Inducement Award Plan and the award agreements covering the grants. These awards follow Nasdaq Listing Rule 5635(c)(4) and are intended as

    6/10/26 4:15:00 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fortrea upgraded by TD Cowen with a new price target

    TD Cowen upgraded Fortrea from Hold to Buy and set a new price target of $15.00

    3/9/26 8:42:40 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea upgraded by Truist with a new price target

    Truist upgraded Fortrea from Hold to Buy and set a new price target of $22.00

    1/8/26 8:10:34 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Fortrea from In-line to Outperform and set a new price target of $25.00

    1/6/26 8:26:05 AM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Russell Erin L bought $100,018 worth of shares (9,854 units at $10.15) (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    9/4/25 4:39:23 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Director Neupert Peter M bought $407,150 worth of shares (62,500 units at $6.51), increasing direct ownership by 175% to 98,132 units (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    8/11/25 8:21:29 PM ET
    $FTRE
    Medical Specialities
    Health Care

    General Counsel Hanson James S. bought $50,600 worth of shares (2,000 units at $25.30), increasing direct ownership by 37% to 7,475 units (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    6/12/24 6:28:42 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Leadership Updates

    Live Leadership Updates

    View All

    Fortrea Appoints Agnieszka Gallagher as General Counsel

    DURHAM, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced the appointment of Agnieszka (Aggie) M. Gallagher as general counsel. Gallagher is responsible for the Company's legal strategy and operations, serving as corporate secretary, chief compliance officer and as a member of Fortrea's leadership team. She succeeds J. Stillman Hanson, who is leaving the Company after a planned transition period. "Aggie brings broad and deep executive experience in the life sciences and beyond to Fortrea, with a track record of navigating complexity in global companies," said Anshul Thakral, CEO of Fortrea.

    11/17/25 7:00:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Appoints William Sharbaugh to Board of Directors

    DURHAM, N.C., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced the appointment of William Sharbaugh to the Company's Board of Directors. Mr. Sharbaugh brings extensive healthcare experience in finance, operations, manufacturing, and quality to the position, having served in executive and board roles during his more than three decades in the pharmaceutical industry. "I'm delighted to welcome Bill to the Fortrea Board, bringing an impressive background in CRO and pharmaceutical operations," said Anshul Thakral, CEO of Fortrea. "He is a highly respected leader, who understands our stakeholders a

    9/22/25 4:30:50 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Appoints Tracy Krumme as Senior Vice President, Investor Relations

    DURHAM, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced the appointment of Tracy Krumme as senior vice president, investor relations, succeeding Hima Inguva in this role, who has decided to pursue other career opportunities. Krumme will report to Chief Financial Officer, Jill McConnell, and lead Fortrea's global investor relations strategy, serving as a key liaison to the investment community. "Tracy is a seasoned executive with the strategic mindset and investor acumen needed as Fortrea enters its next chapter," said McConnell. "She brings not only deep capital markets expertise but also integrity, insi

    8/5/25 6:00:02 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Financials

    Live finance-specific insights

    View All

    Fortrea Announces Date for Second Quarter 2026 Financial Results and Conference Call

    DURHAM, N.C., July 13, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its second quarter 2026 financial results before the market opens on Wednesday, July 29, 2026. The Company will host a conference call at 8:00 a.m. ET on that day to discuss the results. To participate in the conference call, participants should pre-register via the call registration link. All registrants will receive dial-in details and a unique PIN providing access to the live call. To avoid potential delays, participants are encouraged to join at least 10 minutes prior to the start of the call. The live webca

    7/13/26 9:00:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Reports First Quarter 2026 Results

    Strong first-quarter performance reinforces confidence in FY 2026 guidanceBook-to-bill of 1.15x is third consecutive quarter above 1.1x Highlights For the three months ended March 31, 2026: Revenues of $636.5 millionBook-to-bill ratio of 1.15x, resulting in 1.05x book-to-bill for the trailing 12 monthsGAAP net loss of $(23.6) million, or $(0.25) per diluted shareAdjusted EBITDA of $47.0 millionAdjusted net income of $15.2 million, or $0.16 per diluted shareFull-year guidance affirmed DURHAM, N.C., May 05, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization ("CRO"), today reported financial results for the first quarter ended M

    5/5/26 6:00:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Announces Date for First Quarter 2026 Financial Results and Conference Call

    DURHAM, N.C., April 21, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its first quarter 2026 financial results before the market opens on Tuesday, May 5, 2026. The Company will host a conference call at 8:00 a.m. ET on that day to discuss the results. To participate in the conference call, participants should pre-register via the call registration link. All registrants will receive dial-in details and a unique PIN providing access to the live call. To avoid potential delays, participants are encouraged to join at least 10 minutes prior to the start of the call. The live webcast c

    4/21/26 8:45:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fortrea Holdings Inc.

    SC 13G - Fortrea Holdings Inc. (0001965040) (Subject)

    11/12/24 9:55:14 AM ET
    $FTRE
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Fortrea Holdings Inc. (Amendment)

    SC 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)

    5/28/24 5:10:47 PM ET
    $FTRE
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Fortrea Holdings Inc. (Amendment)

    SC 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)

    2/26/24 7:01:18 PM ET
    $FTRE
    Medical Specialities
    Health Care